Article
Oncology
Rachel E. E. Sargent, Emily Siegel, Fumito Ito, Katherine Kramme, Elizabeth Kraft, Vera Hendrix, Azadeh A. A. Carr, Maria E. E. Nelson, Shelly X. X. Bian, Priya Jayachandran, Stephen F. F. Sener
Summary: This retrospective study aimed to determine the rate of axillary lymph node recurrence in patients with pretreatment biopsy-proven axillary metastases and who were clinically node-negative after neoadjuvant chemotherapy (NAC) using wire-directed (WD) sentinel lymph node dissection (SLND). The results showed that axillary node recurrence was very rare after WD SLND for patients who had pretreatment biopsy-proven node metastases and were ypN0 after NAC. These patients would not likely benefit from additional completion ALND to SLND.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Amparo Garcia-Tejedor, Carlos Ortega-Exposito, Sira Salinas, Ana Luzardo-Gonzalez, Catalina Falo, Evelyn Martinez-Perez, Hector Perez-Montero, M. Teresa Soler-Monso, Maria-Teresa Bajen, Ana Benitez, Raul Ortega, Anna Petit, Anna Guma, Miriam Campos, Maria J. Pla, Sonia Pernas, Judith Penafiel, Carlos Yeste, Miguel Gil-Gil, Ferran Guedea, Jordi Ponce, Maria Laplana
Summary: This study aims to evaluate whether axillary radiotherapy (ART) is non-inferior to axillary lymph node dissection (ALND) in patients with limited lymphatic involvement after neoadjuvant systemic treatment (NST), and whether it reduces surgery-related adverse effects.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Gulisa Turashvili, Sandra Gjorgova Gjeorgjievski, Qun Wang, Abdulwahab Ewaz, Di Ai, Xiaoxian Li, Sunil S. Badve
Summary: Although there is a slightly higher discrepancy rate between remote telepathology and conventional on-site assessment for axillary sentinel lymph node evaluation, overall there is no significant difference between the two methods. Further studies are needed to ensure the accuracy of axillary sentinel lymph node assessment via telepathology.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Chemistry, Multidisciplinary
Binge Deng, Yaohui Wang, Yifan Wu, Wenjin Yin, Jinsong Lu, Jian Ye
Summary: The nontoxic Raman nanoparticle tracer GERTs allows for accurate identification of SLNs within 10 minutes in white New Zealand rabbit models, providing surgeons with over 4 hours to distinguish between SLNs and 2nd LNs. Additionally, GERTs have ultrahigh sensitivity, allowing for preoperative positioning information for minimally invasive surgery with no significant toxicity demonstrated in biosafety evaluations.
Article
Medicine, General & Internal
Hee Jun Choi, Jai Min Ryu, Jun Ho Lee, Yoonju Bang, Jongwook Oh, Byung-Joo Chae, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Se Kyung Lee, Jonghan Yu
Summary: This study evaluated the prognostic value of the number of lymph nodes removed in breast cancer patients who underwent axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC). The results showed that in certain subgroups, patients with less than 10 lymph nodes removed had worse prognosis and may require closer monitoring.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Maria Cristina Leonardi, Camilla Arrobbio, Sara Gandini, Stefania Volpe, Francesca Colombo, Eliana La Rocca, Viviana Galimberti, Sabrina Kahler-Ribeiro-Fontana, Cristiana Fodor, Samantha Dicuonzo, Damaris Patricia Rojas, Maria Alessia Zerella, Anna Morra, Emilia Montagna, Marco Colleoni, Giovanni Mazzarol, Laura Lavinia Travaini, Mattia Zaffaroni, Paolo Veronesi, Roberto Orecchia, Barbara Alicja Jereczek-Fossa
Summary: This study aimed to evaluate the rate of positive non-sentinel lymph nodes in breast cancer patients after neoadjuvant systemic therapy following positive sentinel lymph node biopsy. Positive non-SLNs were found in 62.3% of cases and were significantly associated with older age, clinically positive lymph nodes, SLN extracapsular extension, and a higher ratio of positive SLNs/total SLNs. ECE and higher nodal ratio were independent predictors of III axillary level positivity.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Christian Siso, Antonio Esgueva, Joaquin Rivero, Clara Morales, Ignacio Miranda, Vicente Peg, Antonio Gil-Moreno, Martin Espinosa-Bravo, Isabel T. Rubio
Summary: This study evaluated the safety and accuracy of intraoperative ultrasound-guided targeted axillary dissection (TAD) in breast cancer patients with positive lymph nodes after neoadjuvant systemic therapy (NST). The study confirmed the feasibility and accuracy of IOUS guided surgery for axillary staging after NST and highlighted the significance of residual axillary disease in recurrence.
Article
Oncology
Frederikke Munck, Inge S. Andersen, Ilse Vejborg, Maria K. Gerlach, Charlotte Lanng, Niels T. Kroman, Tove H. F. Tvedskov
Summary: Targeted axillary dissection (TAD) with I-125 seed marking before neoadjuvant chemotherapy (NACT) is feasible and provides accurate axillary staging for breast cancer patients. This method reduces the need for re-marking before surgery and has a high identification rate (IR) of the marked lymph node (MLN) and sentinel lymph node (SLNB).
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Ian Campbell, Neil Wetzig, Owen Ung, David Espinoza, Gelareh Farshid, John Collins, James Kollias, Val Gebski, Rebecca Mister, R. John Simes, Martin R. Stockler, Grantley Gill
Summary: For early breast cancer patients who are clinically node-negative, sentinel node-based management (SNBM) is the international standard of care. In the SNAC1 study, we report the rates of axillary recurrence, overall survival, and breast cancer-specific survival at 10 years.
Article
Oncology
Jung Whan Chun, Jisun Kim, I. I. Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sei-Hyun Ahn, Sae Byul Lee
Summary: The study found no significant statistical difference in overall survival and axillary recurrence-free survival between patients with 1-3 sentinel node-positive breast cancer after neoadjuvant chemotherapy who underwent only SLNB or completed ALND.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Ji Young You, Eun Sook Lee, Siew Kuan Lim, Youngmee Kwon, So-Youn Jung
Summary: According to the study, performing sentinel lymph node biopsy (SLNB) without axillary lymph node dissection (ALND) may be a reasonable treatment option for patients with positive lymph nodes after breast cancer surgery. There was no significant difference in the loco-regional recurrence rates between SLNB with ALND and SLNB alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Peiyong Li, Ciqiu Yang, Junsheng Zhang, Yitian Chen, Xiaoqi Zhang, Minting Liang, Na Huang, Yilin Chen, Kun Wang
Summary: Sentinel lymph node biopsy can provide survival results equivalent to axillary lymph node dissection for patients with cN0 and T1-2 breast cancer; however, whether it can be performed on patients with T3-4c breast cancer is still controversial.
Article
Oncology
Chenlu Liang, Liuyi Li, Meizhen Zhu, Jiejie Hu, Yang Yu
Summary: The study indicates that the number of positive SLNs detected via FS plays an important role in guiding intraoperative ALND. The accuracy rate of positive SLN detection via FS is high, which can help avoid unnecessary ALND surgery in some patients.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Betty Fan, Kelsey Romatoski, Jaime Pardo, Monica Valero, Stephanie Serres, Rene Flores, Ted James
Summary: In this retrospective study using a national cancer database, the researchers found that neoadjuvant chemotherapy does not have an effect on lymph node yield following axillary lymph node dissection in breast cancer patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jennifer L. Baker, Farnaz Haji, Amy M. Kusske, Cheryce P. Fischer, Anne C. Hoyt, Carlie K. Thompson, Minna K. Lee, Deanna Attai, Maggie L. DiNome
Summary: This study evaluated the feasibility of localizing metastatic lymph nodes with SAVI reflector prior to neoadjuvant chemotherapy for targeted removal at surgery, showing successful localization in some patients and potential advantages in lymph node detection post-surgery.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
